SG11201908971RA - Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene - Google Patents
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion geneInfo
- Publication number
- SG11201908971RA SG11201908971RA SG11201908971RA SG11201908971RA SG 11201908971R A SG11201908971R A SG 11201908971RA SG 11201908971R A SG11201908971R A SG 11201908971RA SG 11201908971R A SG11201908971R A SG 11201908971RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- yalelaan
- utrecht
- erbb
- cells
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 2
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 2
- 101150029707 ERBB2 gene Proteins 0.000 abstract 1
- 101150038921 NRG1 gene Proteins 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 230000002759 chromosomal effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT o °nolo ono! oni omoilimio oimIE (10) International Publication Number WO 2018/182422 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) C07K 16/28 (2006.01) C07K 16/32 (2006.01) (21) International Application Number: PCT/NL2018/050206 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164292.9 31 March 2017 (31.03.2017) EP (71) Applicant: MERUS N.V. [NL/NL]; Yalelaan 62, 3584 CM Utrecht (NL). (72) Inventors: THROSEY, Mark; c/o Yalelaan 62, 3584 CM Utrecht (NL). GEUIJEN, Cecilia Ana Wilhelmina; c/o Yalelaan 62, 3584 CM Utrecht (NL). MAUSSANG-DE- TAILLE, David Andre Baptiste; c/o Yalelaan 62, 3584 CM Utrecht (NL). LOGTENBERG, Ton; c/o Yalelaan 62, 3584 CM Utrecht (NL). (74) Agent: JANSEN, C.M.; V.O., Carnegieplein 5, 2517 KJ Den Haag (NL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 00 1-1 (54) Title: ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT F CELLS THAT HAVE 00 AN NRG1 FUSION GENE 0 (57) : The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies \" for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene 0 comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164292 | 2017-03-31 | ||
PCT/NL2018/050206 WO2018182422A1 (en) | 2017-03-31 | 2018-04-03 | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908971RA true SG11201908971RA (en) | 2019-10-30 |
Family
ID=58488840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908971R SG11201908971RA (en) | 2017-03-31 | 2018-04-03 | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
Country Status (14)
Country | Link |
---|---|
US (1) | US11780925B2 (en) |
EP (1) | EP3600413A1 (en) |
JP (1) | JP2020511993A (en) |
KR (1) | KR20190140945A (en) |
CN (1) | CN110650752A (en) |
AU (1) | AU2018246873B2 (en) |
BR (1) | BR112019020508A2 (en) |
CA (1) | CA3058343A1 (en) |
EA (1) | EA201992063A1 (en) |
IL (2) | IL310223A (en) |
MX (1) | MX2019011660A (en) |
PH (1) | PH12019550202A1 (en) |
SG (1) | SG11201908971RA (en) |
WO (1) | WO2018182422A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
ES2865482T3 (en) | 2015-10-23 | 2021-10-15 | Merus Nv | Binding molecules that inhibit cancer growth |
MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
MX2020001432A (en) | 2017-08-09 | 2020-03-20 | Merus Nv | Antibodies that bind egfr and cmet. |
CN111936514A (en) * | 2018-03-30 | 2020-11-13 | 美勒斯公司 | Multivalent antibodies |
CN114426578A (en) * | 2019-02-14 | 2022-05-03 | 美勒斯公司 | Combination of binding moieties that bind EGFR, HER2 and HER3 |
EP3947440A1 (en) * | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for generating avid-binding multispecific antibodies |
GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
CA3158609A1 (en) * | 2019-10-24 | 2021-04-29 | Merus N.V. | Means and methods for treating subjects with her2 and her3 positive cancer |
CN115362270A (en) * | 2020-01-29 | 2022-11-18 | 得克萨斯州大学系统董事会 | Use of an EGFR/HER2 tyrosine kinase inhibitor and/or a HER2/HER3 antibody in the treatment of cancer with NRG1 fusion |
EP4110472A1 (en) * | 2020-02-28 | 2023-01-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
TW202227504A (en) * | 2020-10-15 | 2022-07-16 | 大陸商上海翰森生物醫藥科技有限公司 | Anti-erbb3 antibody, antigen binding fragment thereof and medical use thereof |
US20240026029A1 (en) * | 2020-11-04 | 2024-01-25 | Merus N.V. | Means and methods for treating subjects with erbb3 mutation positive cancer |
EP4304636A1 (en) * | 2021-03-11 | 2024-01-17 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
TW202328191A (en) | 2021-09-03 | 2023-07-16 | 英商癌症研究科技有限公司 | Treatment and prevention of cancer using her3 antigen-binding molecules |
CN114410776B (en) * | 2021-12-21 | 2023-08-25 | 南京世和医疗器械有限公司 | Detection method and kit for NRG1 fusion gene |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (en) | 1987-10-28 | 1989-04-29 | Oncogen | HUMANIMMUGLOBULIN SOM PRODUCERATS MED HYBRID-DNA-TEKNIK. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JP3502093B2 (en) | 1991-07-15 | 2004-03-02 | ザ・ウエルカム・ファウンデーション・リミテッド | Production of antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
CN100457914C (en) | 1999-04-15 | 2009-02-04 | 荷兰克鲁塞尔公司 | Recombinant protein production in human cell using sequences encoding adenovirus E1 protein |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
MXPA03011801A (en) | 2001-07-04 | 2005-03-07 | Chromagenics Bv | Method of selecting dna sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity. |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
WO2003107218A1 (en) | 2002-05-31 | 2003-12-24 | セレスター・レキシコ・サイエンシズ株式会社 | Interaction predicting device |
EP1523496B1 (en) | 2002-07-18 | 2011-06-29 | Merus B.V. | Recombinant production of mixtures of antibodies |
DE602004002275T2 (en) | 2003-01-07 | 2007-09-06 | Symphogen A/S | PROCESS FOR PRODUCING RECOMBINANT POLYCLONAL PROTEINS |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
EP1778270A4 (en) | 2004-05-05 | 2009-09-02 | Merrimack Pharmaceuticals Inc | Bispecific binding agents for modulating biological activity |
ES2526343T3 (en) | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anti-CD3 antibodies and methods of use thereof |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
AU2005327973A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
EP3248617A3 (en) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
ES2593484T3 (en) | 2007-03-29 | 2016-12-09 | Genmab A/S | Bispecific antibodies and their production methods |
US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
SI2173379T1 (en) | 2007-07-02 | 2015-12-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
WO2009051974A1 (en) | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | Her-2 diagnostic methods |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP5530367B2 (en) | 2008-02-05 | 2014-06-25 | ザイムワークス,インコーポレイテッド | Method for determining correlated residues in proteins or other biopolymers using molecular dynamics |
EP3456193A1 (en) | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
CN102137874B (en) | 2008-08-29 | 2015-02-18 | 西福根有限公司 | Recombinant anti-epidermal growth factor receptor antibody compositions |
CN102282168A (en) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | Human serum albumin linkers and conjugates thereof |
WO2010083470A1 (en) | 2009-01-15 | 2010-07-22 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-3 |
CN104262483A (en) | 2009-01-26 | 2015-01-07 | 根马布股份公司 | Methods For Producing Mixtures Of Antibodies |
TW201544123A (en) | 2009-03-20 | 2015-12-01 | Genentech Inc | Anti-HER antibodies |
JP2012525149A (en) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Method for making heteromultimeric molecules |
CN102471378B (en) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | Readily isolated bispecific antibodies with native immuneoglobulin format |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
BR112012003809A2 (en) | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | isolated monoclonal antibody or antigen binding portion thereof, composition and method for treating cancer in an individual. |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US10208128B2 (en) | 2009-11-04 | 2019-02-19 | Affibody Ab | HER3 binding polypeptides |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
RU2724663C2 (en) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Mouse with common light chain |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
BR112013004012B1 (en) | 2010-08-20 | 2021-03-23 | Novartis Ag | ISOLATED MONOCLONAL ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THE SAME TO THE HER3 RECEPTOR, ITS USE AND PHARMACEUTICAL COMPOSITION |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
CN103547598A (en) | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | Combination therapies comprising anti-ERBB 3 agents |
CA2828075A1 (en) | 2011-03-11 | 2012-09-20 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
US20150231238A1 (en) | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
MX358752B (en) | 2011-03-25 | 2018-08-31 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins. |
US9346883B2 (en) | 2011-05-13 | 2016-05-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies against HER3 |
CA2840461A1 (en) | 2011-06-20 | 2012-12-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbb3 antibody |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
IN2014CN03042A (en) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
DK2797957T3 (en) | 2011-11-23 | 2019-09-23 | Medimmune Llc | BINDING MOLECULES SPECIFIC TO HER3 AND APPLICATIONS THEREOF |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
EA201491120A1 (en) | 2011-12-05 | 2015-07-30 | Новартис Аг | ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN III AND DOMAIN IV HER3 |
EP2823270B1 (en) | 2012-03-09 | 2022-05-04 | Promega Corporation | pH SENSORS |
RU2014136886A (en) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | DIAGNOSTIC AND TREATMENT TYPES RELATED TO HER3 INHIBITORS |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
SG10201607371UA (en) | 2012-04-20 | 2016-10-28 | Merus Nv | Methods and means for the production of ig-like molecules |
TWI641619B (en) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
SG10201705787VA (en) | 2012-09-27 | 2017-08-30 | Merus Nv | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
WO2014060365A1 (en) | 2012-10-15 | 2014-04-24 | Universität Zürich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
EA031184B1 (en) | 2012-11-21 | 2018-11-30 | Янссен Байотек, Инк. | BISPECIFIC EGFR/c-Met ANTIBODIES |
EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
CA2900955A1 (en) | 2013-03-14 | 2014-10-02 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
CN105264382A (en) | 2013-04-05 | 2016-01-20 | 美国控股实验室公司 | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of HER3 activation |
CA2910945A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
EP3030577B1 (en) * | 2013-08-07 | 2019-10-02 | Universität zu Köln | Novel nrg1 fusion genes in cancer |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
WO2015066543A1 (en) | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
EP3470435B1 (en) | 2014-02-28 | 2020-08-05 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
MA41123A (en) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | POLYTHERAPY FOR CANCER TREATMENT |
CA2991880A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
ES2865482T3 (en) | 2015-10-23 | 2021-10-15 | Merus Nv | Binding molecules that inhibit cancer growth |
US20200291130A1 (en) | 2017-03-31 | 2020-09-17 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
CN111148764A (en) | 2017-05-17 | 2020-05-12 | 美勒斯公司 | Combinations of ErbB-2/ErbB-3 bispecific antibodies and endocrine therapy for breast cancer |
MX2020001432A (en) | 2017-08-09 | 2020-03-20 | Merus Nv | Antibodies that bind egfr and cmet. |
-
2018
- 2018-04-03 MX MX2019011660A patent/MX2019011660A/en unknown
- 2018-04-03 JP JP2019553404A patent/JP2020511993A/en active Pending
- 2018-04-03 EP EP18717733.2A patent/EP3600413A1/en active Pending
- 2018-04-03 CA CA3058343A patent/CA3058343A1/en active Pending
- 2018-04-03 IL IL310223A patent/IL310223A/en unknown
- 2018-04-03 AU AU2018246873A patent/AU2018246873B2/en active Active
- 2018-04-03 CN CN201880028922.XA patent/CN110650752A/en active Pending
- 2018-04-03 IL IL269656A patent/IL269656B1/en unknown
- 2018-04-03 BR BR112019020508-0A patent/BR112019020508A2/en unknown
- 2018-04-03 SG SG11201908971R patent/SG11201908971RA/en unknown
- 2018-04-03 EA EA201992063A patent/EA201992063A1/en unknown
- 2018-04-03 WO PCT/NL2018/050206 patent/WO2018182422A1/en active Application Filing
- 2018-04-03 US US16/499,185 patent/US11780925B2/en active Active
- 2018-04-03 KR KR1020197032398A patent/KR20190140945A/en not_active Application Discontinuation
-
2019
- 2019-09-27 PH PH12019550202A patent/PH12019550202A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018246873B2 (en) | 2021-05-06 |
EA201992063A1 (en) | 2020-03-26 |
WO2018182422A8 (en) | 2019-10-31 |
IL269656B1 (en) | 2024-02-01 |
BR112019020508A2 (en) | 2020-08-04 |
CA3058343A1 (en) | 2018-10-04 |
US20200102393A1 (en) | 2020-04-02 |
JP2020511993A (en) | 2020-04-23 |
MX2019011660A (en) | 2019-11-18 |
WO2018182422A1 (en) | 2018-10-04 |
EP3600413A1 (en) | 2020-02-05 |
AU2018246873A1 (en) | 2019-10-17 |
IL310223A (en) | 2024-03-01 |
US11780925B2 (en) | 2023-10-10 |
CN110650752A (en) | 2020-01-03 |
IL269656A (en) | 2019-11-28 |
KR20190140945A (en) | 2019-12-20 |
PH12019550202A1 (en) | 2020-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
SG11201908513RA (en) | Peptides for treatment of diabetes | |
SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |